Researchers demonstrated that the antibody-mediated neutralization or gene-editing technology-mediated inactivation of GM-CSF in CAR-Ts can eliminate macrophage-secreted CRS biomarkers such as MCP-1, IL-6, and IL-8, significantly reducing neurotoxicity and CRS occurrence. The gene discussed is CSF2; the disease is congenital rubella syndrome.